Myomo Inc. filings document material events for a Delaware medical-device company focused on wearable robotics and the MyoPro powered upper-limb orthosis. Recent Form 8-K disclosures furnish quarterly and annual operating results, revenue sources, MyoPro orders and authorizations, patient-pipeline activity, and exhibits tied to financial press releases.
The filing record also covers governance and capital-structure matters, including board appointments, director compensation arrangements, indemnification agreements, and loan and security agreements. These disclosures describe formal reporting of operating performance, financing terms, corporate governance actions and related risk and control subjects for MYO.
MYOMO, INC. (MYO) reported that Chief Medical Officer Harry Kovelman sold 15,488 shares of common stock on September 11, 2026 in an open-market or private transaction at a weighted-average price of $1.2709 per share, with individual trade prices ranging from $1.25 to $1.29 per share.
After this sale, he directly holds 90,245 shares of MYOMO common stock. No transactions in this filing are reported as made under a Rule 10b5-1 trading plan.
MYOMO, INC. (MYO) received a notice under Rule 144 that Harry Franklin Kovelman plans to sell common stock. The planned sale covers 15,844 shares of MYO common stock through Morgan Stanley Smith Barney’s Executive Financial Services, with an indicated aggregate market value of $20,136.14, and is listed for trading on the NYSE as of September 11, 2026. The shares to be sold were acquired upon the vesting of restricted stock between June 27, 2024 and June 15, 2025. Kovelman also reports prior Rule 144 sales in the last three months, including 17,500 shares sold on August 20, 2026 for $30,329.25 and 10,442 shares sold on June 12, 2026 for $12,514.74.
MYOMO, INC. (MYO) director Morris Milton Mayo reported selling 15,000 shares of Common Stock on September 2, 2026 in a single lot at $1.41 per share in an open market or private transaction. Following this sale, he directly holds 208,391 shares of MYO common stock. No Rule 10b5-1 trading plan is reported.
MYOMO, INC. (MYO) has a notice of proposed sale filed under Rule 144 for shares held by director Morris Milton Mayo. The filing covers the potential sale of 15,000 shares of common stock through RBC Capital Markets LLC, with an indicated aggregate market value of $21,150.00 and listing on the NYSE.
The securities relate to previously vested restricted stock units, including 14,997 shares acquired on March 7, 2024 and 3 shares acquired on December 5, 2024 from the issuer.
MYOMO, INC. (MYO) reports an amended insider transaction for Chief Medical Officer Harry Kovelman. On August 20, 2026, he executed an open-market sale of 17,500 shares of common stock at a weighted average price of $1.7331 per share, with individual trade prices ranging from $1.72 to $1.75. Following this transaction, he beneficially owned 105,733 shares of MYO common stock. The amendment corrects the originally reported shares sold and resulting holdings; no other aspects of the prior filing were changed.
MYOMO, INC. (MYO) reported that Chief Medical Officer Harry Kovelman sold common stock in an open-market transaction. On 2026-08-20, he sold 17,250 shares at a weighted average price of $1.7331 per share, with individual sale prices ranging from $1.72 to $1.75. Following this sale, he directly holds 105,983 shares of MYO common stock. The transaction was not reported as being made under a Rule 10b5-1 trading plan.
MYOMO, INC. (MYO) is the issuer for a notice by officer Harry Franklin Kovelman to sell company common stock under Rule 144. The notice covers up to 17,500 shares of common stock to be sold through Morgan Stanley Smith Barney LLC. The securities to be sold were acquired upon the vesting of restricted stock during the period from 07/10/2024 through 06/05/2026. The filing also lists prior sales of MYOMO common stock by the same person over the past three months.
Myomo, Inc. (MYO) received an amended Schedule 13G/A from Rosalind Advisors, Inc., Rosalind Master Fund L.P. and related individuals, updating their beneficial ownership disclosure. Rosalind Master Fund L.P. is reported as beneficially owning 3,637,886 shares of common stock, representing approximately 9.18% of Myomo’s outstanding common stock, based on 39,607,854 shares outstanding as of July 31, 2026. The group also holds 3,763,258 additional shares issuable upon exercise of pre-funded warrants, but a 9.99% blocker provision prevents exercising these warrants to the extent it would push beneficial ownership above 9.99%. As a result, the reporting persons state they were not able to exercise any of the warrants at the event date. Rosalind Advisors acts as investment advisor to the fund, and Steven Salamon as portfolio manager; both may be deemed beneficial owners but expressly disclaim beneficial ownership of the shares.
MYOMO, INC.'s Chief Medical Officer, Harry Kovelman, reported equity compensation activity involving common stock. On August 7, 2026, he received a grant of 55,149 fully vested Restricted Stock Units as payment for incentive compensation earned for the fiscal year ended December 31, 2025. On the same date, 22,457 shares were disposed of and withheld solely to pay income and other taxes associated with the vesting of these RSUs.
Myomo, Inc. reported that Chief Commercial Officer Micah Mitchell received a grant of 58,409 shares of Common Stock on August 7, 2026 as fully vested Restricted Stock Units paid as incentive compensation for the fiscal year ended December 31, 2025. On the same date, 21,559 shares were withheld and disposed of at $1.42 per share to pay related income and other taxes.